76 related articles for article (PubMed ID: 38711006)
1. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
[TBL] [Abstract][Full Text] [Related]
3. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.
Wolf SL; Barton DL; Qin R; Wos EJ; Sloan JA; Liu H; Aaronson NK; Satele DV; Mattar BI; Green NB; Loprinzi CL
Support Care Cancer; 2012 Mar; 20(3):625-32. PubMed ID: 21479990
[TBL] [Abstract][Full Text] [Related]
4. Neuropathic Pain Affects Quality of Life in Breast Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy.
Jheng YW; Chan YN; Wu CJ; Lin MW; Tseng LM; Wang YJ
Pain Manag Nurs; 2024 Jun; 25(3):308-315. PubMed ID: 38278750
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.
Barton DL; Wos EJ; Qin R; Mattar BI; Green NB; Lanier KS; Bearden JD; Kugler JW; Hoff KL; Reddy PS; Rowland KM; Riepl M; Christensen B; Loprinzi CL
Support Care Cancer; 2011 Jun; 19(6):833-41. PubMed ID: 20496177
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neuropathy and pain in pediatric oncology patients: impact of combination therapies.
Soriano D; Santos Chocler G; Varela MA; Coronel MF
Eur J Pediatr; 2024 Jun; ():. PubMed ID: 38856761
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Zenatri M; Perennec T; Michon C; Gernier F; Grellard JM; Piloquet FX; Dubot-Poitelon C; Kalbacher E; Tredan O; Augereau P; Pautier P; Fey L; Joly F; Frenel JS
Gynecol Oncol; 2024 May; 187():139-144. PubMed ID: 38776631
[TBL] [Abstract][Full Text] [Related]
8. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes.
Li T; Trinh T; Bosco A; Kiernan MC; Goldstein D; Park SB
Support Care Cancer; 2024 Apr; 32(5):278. PubMed ID: 38592525
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
Chen CS; Zirpoli G; Budd GT; Barlow WE; Pusztai L; Hortobagyi GN; Albain KS; Godwin AK; Thompson A; Henry NL; Ambrosone CB; Stringer KA; Hertz DL
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38814343
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review.
Johnson KB; Sharma A; Henry NL; Wei M; Bie B; Hershberger CE; Rhoades EE; Sen A; Johnson RE; Steenblik J; Hockings J; Budd GT; Eng C; Foss J; Rotroff DM
Front Pain Res (Lausanne); 2023; 4():1139883. PubMed ID: 37251592
[TBL] [Abstract][Full Text] [Related]
11. A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.
Schönsteiner SS; Bauder Mißbach H; Benner A; Mack S; Hamel T; Orth M; Landwehrmeyer B; Süßmuth SD; Geitner C; Mayer-Steinacker R; Riester A; Prokein A; Erhardt E; Kunecki J; Eisenschink AM; Rawer R; Döhner H; Kirchner E; Schlenk RF
Exp Hematol Oncol; 2017; 6():5. PubMed ID: 28194306
[TBL] [Abstract][Full Text] [Related]
12. Effect of Silybum Marianum on Reduction of Chemotherapy-Induced Peripheral Neurotoxicity with Cisplatin.
Gholami AH; Ansari H; Dadkhah A
Adv Biomed Res; 2024; 13():21. PubMed ID: 38808323
[TBL] [Abstract][Full Text] [Related]
13. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract][Full Text] [Related]
14. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.
Vasquez S; Guidon M; McHugh E; Lennon O; Grogan L; Breathnach OS
Ir J Med Sci; 2014 Mar; 183(1):53-8. PubMed ID: 23832573
[TBL] [Abstract][Full Text] [Related]
16. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
17. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
[TBL] [Abstract][Full Text] [Related]
18. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.
Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C
Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
